Combigan is indicated to reduce elevated intraocular pressure (IOP) in glaucoma or ocular hypertension where adjunctive or replacement therapy is warranted. It combines brimonidine tartrate, an alpha-adrenergic receptor agonist, and timolol maleate, a beta-adrenergic receptor inhibitor. Each of these ingredients decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
Combigan is already supplied as a 0.2%/0.5% strength solution in 5mL and 10mL bottles.
For more information call (800) 433-8871 or visit Combigan.com.